관절내 점성보충 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Viscosupplementation Market was valued at USD 4.9 billion in 2025 and is estimated to grow at a CAGR of 8.5% to reach USD 11 billion by 2035.

The viscosupplementation market is experiencing strong growth, supported by the rising adoption of intra-articular hyaluronic acid therapies and a growing shift toward minimally invasive treatment approaches. The increasing prevalence of joint-related disorders and demand for effective non-surgical solutions are driving widespread acceptance of these therapies. Hyaluronic acid-based injections are gaining traction for their ability to improve joint function, reduce discomfort, and enhance mobility over a sustained period. Healthcare providers are increasingly recommending such procedures as part of conservative management strategies, which is accelerating global adoption. Continuous advancements in formulation technologies and growing awareness regarding early intervention are further strengthening market expansion. Additionally, improving healthcare access and rising focus on patient-centric treatment solutions are contributing to the increased utilization of viscosupplementation. These factors collectively position the market for steady long-term growth across developed and emerging regions.

Viscosupplementation is widely used as a therapeutic approach for managing joint conditions through the administration of hyaluronic acid into affected areas. This treatment helps restore joint lubrication, minimize friction, relieve pain, and improve overall mobility. It is considered an effective alternative to surgical procedures and is extensively applied in orthopedic and sports medicine practices. The growing preference for less invasive treatment methods continues to support its increasing adoption, as patients and healthcare providers seek solutions that reduce recovery time and procedural risks while maintaining effectiveness.

The single injection segment is anticipated to grow at a CAGR of 8.9% through 2035, driven by its ease of administration and reduced need for multiple clinical visits. Improved patient adherence and advancements in hyaluronic acid formulations that deliver extended relief with fewer doses are contributing to the segment's growth.

The non-avian origin segment accounted for 71.5% share in 2025 and is expected to reach USD 7.8 billion by 2035. Growth in this segment is supported by factors such as lower risk of adverse reactions, consistent product quality, and broader acceptance among patients and healthcare providers. These advantages are driving increased adoption across various treatment settings.

North America Viscosupplementation Market held a share of 42.1% in 2025, supported by a high incidence of joint-related conditions and well-established healthcare systems. The region benefits from strong healthcare spending, access to advanced treatment options, and the presence of major market participants. Increasing awareness regarding non-surgical therapies and rising demand for minimally invasive procedures are further reinforcing regional growth.

Key players operating in the Global Viscosupplementation Market include Zimmer Biomet, Sanofi, Anika Therapeutics, Bioventus, Fidia Pharma, IBSA Pharma, Seikagaku Corporation, Avanos Medical, Ferring Pharmaceuticals, TRB Pharma, APTISSEN, Biotech Healthcare, Premier Surgical, and Stellar Pharmaceuticals. Companies in the Global Viscosupplementation Market are adopting a range of strategies to strengthen their competitive position and expand their global presence. Significant investments in research and development are enabling the introduction of advanced formulations with improved efficacy and longer-lasting outcomes. Market participants are focusing on expanding their product portfolios and enhancing manufacturing capabilities to meet growing demand. Strategic partnerships, collaborations, and distribution agreements are helping companies increase market penetration and geographic reach. Additionally, firms are emphasizing regulatory approvals and quality compliance to ensure product reliability. Continuous innovation, along with efforts to improve patient convenience and treatment outcomes, is supporting sustained growth and reinforcing their foothold in the global viscosupplementation industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Source of origin trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 A growing geriatric population prone to osteoarthritis
    • 3.2.1.2 Rising demand for minimally invasive treatments
    • 3.2.1.3 Increasing sports-related injuries
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment cost
    • 3.2.2.2 Availability of alternative treatments
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of advanced hyaluronic acid formulations
    • 3.2.3.2 Expansion of orthopedic and sports medicine clinics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape (Driven by Primary Research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Reimbursement scenario
• 3.7 Future market trends (Driven by Primary Research)
• 3.8 Pipeline analysis
• 3.9 Impact of AI on the market
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Single injection
• 5.3 3 injections
• 5.4 5 injections

Chapter 6 Market Estimates and Forecast, By Source of Origin, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Avian origin
• 6.3 Non-avian origin

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Orthopedic clinics
• 7.4 Ambulatory surgical centers (ASCs)
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Anika Therapeutics
• 9.2 APTISSEN
• 9.3 Avanos Medical
• 9.4 Biotech Healthcare
• 9.5 Bioventus
• 9.6 Ferring Pharmaceuticals
• 9.7 Fidia Pharma
• 9.8 IBSA Pharma
• 9.9 Premier Surgical
• 9.10 Sanofi
• 9.11 Seikagaku Corporation
• 9.12 Stellar Pharmaceuticals
• 9.13 TRB Pharma
• 9.14 Zimmer Biomet